Fenestra HDVC

Description

Alpha-Tocopheryl 2,3,5-Triiodobenzoate is a on non-toxic lipophilic molecule (alpha-tocopherol) with a high ratio of iodinated contrasting material (tri-iodobenzene) and is the main ingredient of the Fenestra HDVC contrast agent used for vascular imaging, functional and anatomical imaging, staging and monitoring fatty liver disease, quantifying liver tumor burdens. The compound was developed in laboratory of Dr. Thierry Vandamme at the University of Strasbourg.

Tumor cells in the liver are not able to take up Fenestra HDVC contrast agent leading to negative tumor contrast in the liver. This is true for both in vivo and ex vivo liver scans (see Tan et al. in publications).

Pancreatic tumors show uptake of the Fenestra vitamin E based contrast agent leading to positive contrast in pancreatic tumors (see Tesson et al. in publications).

Fenestra HDVC is ideal for their research with primary liver and pancreatic cancer because the product can be injected IP or IV and enables longitudinal examinations after a single injection.

The product has twice the dose of iodine (100 mgI/ml) compared to previous Fenestra formulations allowing researchers to reduce the injected dose.

Interested in testing out Fenestra HDVC for liver tumors? Ask us about our CRO services for scanning excised livers with microCT.